Core Points - The article highlights the debut of three companies: He Yuan Bio (688765.SH), Xi'an Yicai (688783.SH), and Bibet (688759.SH) at the Shanghai Stock Exchange listing ceremony on October 28 [1] - These companies are the first batch of new registered firms in the Sci-Tech Innovation Board's growth tier since the "1+6" reform, enhancing the "hard technology" content of the sector [1] Company Summaries - Xi'an Yicai raised a total of 4.636 billion yuan through its initial public offering [1] - He Yuan Bio raised 2.599 billion yuan in its IPO [1] - Bibet secured 1.6 billion yuan from its initial public offering [1] - The total fundraising amount from these three companies is 8.835 billion yuan [1]

Group 1 - N必贝特-U (688759) was listed today, opening with a rise of 175.03%, and closing with a gain of 74.41%, with a total trading volume of 34.03 million shares and a turnover of 1.107 billion yuan, resulting in a turnover rate of 73.25% [2] - Among the four new stocks listed today, N必贝特-U had the smallest increase, while N禾元-U surged by 213.49%, N奕材-U increased by 198.72%, and N泰凯英 rose by 188.53% [2][3] - 必贝特 is a biopharmaceutical company focused on innovative drug development, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders, with a commitment to developing First-in-Class drugs and addressing unmet clinical needs [2] Group 2 - The total issuance of N必贝特-U was 90 million shares, with an online issuance of 21.6 million shares at a price of 17.78 yuan per share, resulting in a final online subscription rate of 0.04772481% [3] - The initial fundraising amount for N必贝特-U was 1.6 billion yuan, primarily allocated to new drug research and development projects, the establishment of a research and development center in Qingyuan, and the construction of a formulation industrialization base, as well as to supplement working capital [3]

中国经济网北京10月28日讯 今日，广州必贝特医药股份有限公司（股票简称：必贝特，股票代码：688759.SH）在上交所科创板上市。该股开盘报 48.90元，截至收盘报31.01元，涨幅74.41%，成交额11.07亿元，振幅104.67%，换手率73.25%，总市值139.56亿元。 如投资者以当日开盘价48.90元买入，截至收盘亏损达36.58%。 必贝特是一家以临床价值为导向、专注于创新药自主研发的生物医药企业。公司聚焦于肿瘤、自身免疫性疾病、代谢性疾病等重大疾病领域，依托 自主研发构建的核心技术平台，持续开发临床急需的全球首创药物（First-in-Class）和针对未满足临床需求的创新药物。 | | 1 1 18 . | | --- | --- | | 117 | . N | 公司实际控制人为钱长庚，无控股股东。本次发行前，钱长庚直接持有公司15.2840%的股份，是公司的第一大股东，同时通过担任广州药擎执行事 务合伙人控制公司8.5899%的股份。钱长庚与蔡雄（直接持有公司11.1364%的股份）、熊燕（直接持有公司8.9479%的股份）签署《一致行动人协议》， 基于上述安排，钱长庚合计控制公司4 ...

Group 1 - N必贝特-U (688759) was listed today, opening with a rise of 175.03%, and closing the morning session with a gain of 93.70%, with a trading volume of 26.41 million shares and a turnover of 867 million yuan, resulting in a turnover rate of 56.85% [1][2] - Among the new stocks listed today, N必贝特-U had the smallest increase compared to others, such as N奕材-U which rose by 210.21%, N泰凯英 which increased by 206.13%, and N禾元-U which saw a rise of 202.96% [1][2] - 必贝特 is a biopharmaceutical company focused on innovative drug development, targeting major diseases such as cancer, autoimmune diseases, and metabolic disorders, with a commitment to developing first-in-class drugs and addressing unmet clinical needs [1] Group 2 - The total number of shares issued by the company is 90 million, with an online issuance of 21.6 million shares at a price of 17.78 yuan per share, resulting in a final online subscription rate of 0.04772481% [2] - The total fundraising amount from the initial public offering (IPO) is 1.6 billion yuan, primarily allocated to new drug research and development projects, the establishment of a research and development center in Qingyuan, and the construction of a formulation industrialization base, as well as to supplement working capital [2]

Market Overview - The A-share market experienced a significant rally, with the Shanghai Composite Index breaking the 4000-point mark for the first time since August 19, 2015, marking a historic moment after ten years [1] - As of the midday session, the Shanghai Composite Index rose by 0.21% to 4005.44 points, while the Shenzhen Component Index increased by 0.52% and the ChiNext Index surged by 1.35% [1] Trading Data - The trading volume for the day reached 1.36 trillion yuan, with over 3000 stocks rising [1] - Specific index performances included: - Shanghai Composite Index: 4005.44, up 8.50 points (0.21%), with a trading volume of 588.4 billion yuan [2] - Shenzhen Component Index: 13559.57, up 70.17 points (0.52%), with a trading volume of 761.1 billion yuan [2] - ChiNext Index: 3277.97, up 43.52 points (1.35%), with a trading volume of 360.3 billion yuan [2] Sector Performance - The Fujian sector showed strong performance, with notable stocks such as Pingtan Development (000592) achieving a significant rise [3] - The nuclear power sector was active, with stocks like Dongfang Tantalum Industry (000962) and Antai Technology (000969) showing gains [3] - The commercial aerospace sector continued its upward trend, with Aerospace Intelligent Equipment (300455) reaching a historical high [3] - The diamond cultivation concept saw a pullback, with stocks like Huifeng Diamond declining over 5% [3] New Listings - Four new stocks were listed on the A-share market, marking a record high for the number of new listings in a single day this year [3] - Notably, three unprofitable companies—Bibet, Xi'an Yicai, and Heyuan Biology—saw significant opening gains, with Xi'an Yicai opening up 360% [3][5] - The introduction of these unprofitable hard-tech companies to the Sci-Tech Innovation Board indicates a smoother path for such firms to go public [5]

Core Points - The A-share market experienced a significant rally, with the Shanghai Composite Index surpassing the 4000-point mark for the first time in ten years, closing at 4005.44 points, up 0.21% [1][6] - The trading volume reached 1.36 trillion yuan, with over 3000 stocks rising [1] - Key sectors showing strong performance included Fujian, nuclear power, and commercial aerospace, while coal and precious metals sectors faced declines [3] Market Performance - The Shanghai Composite Index rose by 8.50 points, or 0.21%, with a trading volume of 588.4 billion yuan [2] - The Shenzhen Component Index increased by 70.17 points, or 0.52%, with a trading volume of 761.1 billion yuan [2] - The ChiNext Index saw a rise of 43.52 points, or 1.35%, with a trading volume of 360.3 billion yuan [2] Sector Highlights - The Fujian sector was particularly strong, with stocks like Pingtan Development achieving significant gains [3] - The nuclear power sector was active, with companies like Dongfang Tantalum and Antai Technology showing notable performance [3] - The commercial aerospace sector continued its upward trend, with Aerospace Intelligence Equipment reaching new historical highs [3] New Listings - Four new stocks were listed on the A-share market, marking a record high for the year [4] - Notably, three unprofitable companies—Bibet, Xi'an Yicai, and Heyuan Biology—saw substantial opening gains, with Xi'an Yicai opening up 360% [4][5] - The introduction of these companies signifies a smoother path for unprofitable hard-tech enterprises to enter the market [5]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) aims to deepen comprehensive reforms in the capital market to enhance its inclusiveness, adaptability, attractiveness, and competitiveness, thereby better serving the "14th Five-Year Plan" development goals and the construction of a financial power [1][7]. Group 1: Market Developments - The first batch of new registered companies in the Sci-Tech Innovation Board's growth layer was listed on October 28, marking a significant advancement in the board's reform and development [1]. - Three unprofitable companies, He Yuan Biological-U (688765.SH), Xi'an Yicai-U (688783.SH), and Bibete-U (688759.SH), collectively went public [1]. - As of now, the number of companies in the Sci-Tech Innovation Board's growth layer has reached 35, with a total of 592 listed companies on the board [6]. Group 2: Regulatory and Institutional Support - The CSRC has successfully implemented the "1+6" reform policy since June, which includes the introduction of professional institutional investors and pre-review systems [5]. - The Shanghai Municipal Government is actively collaborating with the CSRC to enhance the operational stability and functionality of the Sci-Tech Innovation Board [5]. - The Shanghai Stock Exchange (SSE) has completed preparations for rules, technology, and market readiness within four months following the reform policy's release [6]. Group 3: Future Plans and Strategic Focus - The CSRC plans to research and formulate strategic tasks and major initiatives for the capital market during the "14th Five-Year Plan" period, focusing on risk prevention, strong regulation, and promoting high-quality development [7]. - The SSE will focus on four key areas: maintaining the "hard technology" positioning, promoting development through reform, enhancing regulatory effectiveness, and prioritizing investor protection [8].

证券时报·数据宝统计显示，公司本次发行总量为9000.00万股，其中，网上发行量为2160.00万股，发行 价格为17.78元/股，网上发行有效申购户数为383.61万户，网上发行最终中签率为0.04772481%。公司首 发募集资金16.00亿元，募集资金主要投向新药研发项目、清远研发中心及制剂产业化基地建设项目、 补充流动资金项目等。（数据宝） （文章来源：证券时报网） N必贝特-U今日上市，开盘价48.90元，上涨175.03%。 必贝特是一家以临床价值为导向、专注于创新药自主研发的生物医药企业。公司聚焦于肿瘤、自身免疫 性疾病、代谢性疾病等重大疾病领域，依托自主研发构建的核心技术平台，持续开发临床急需的全球首 创药物(First-in-Class)和针对未满足临床需求的创新药物。公司秉承"矢志创新，追求更好"的愿景，坚持 自主创新，致力于研发出具有全球自主知识产权、安全、有效的创新药物。 ...

（文章来源：每日经济新闻） 每经AI快讯，10月28日，必贝特、西安奕材开盘走低，较开盘价跌幅达30%，双双触发临停。禾元生物 高开回落，较开盘价跌幅超10%。10月28日，禾元生物、西安奕材、必贝特三家未盈利公司将登陆科创 板，成为科创板科创成长层首批新注册公司。 ...

消息面上，10月28日，禾元生物、西安奕材、必贝特三家未盈利公司登陆科创板，成为科创板科创成长层 首批新注册公司。 编辑｜钉钉 | < W | | N奕材-U(688783) | | | | | --- | --- | --- | --- | --- | --- | | | | 10-28 09:32:36 融 成 | | | | | 27.85 | | 额 3.28亿 股本 40.38亿 市盈™ -159 | | | 万得 盘口 | | 19.23 | 223.09% 换 5.43% 市值 1125亿 市净" | 8.94 | | | | | 分时 | 五日 日K 周K | | | 中文 | (0 | | 叠加 | 均价:36.65 | | 盘口 | | 资金 | | 40.00 | 364.04% | | 51 +7 | | | | | | | SE DE | | | | 8.62 | 0.00% 买一 | | | | | | | | | ST M | | | | -22.76 | -364.04% | | 25 1 | | | | 09:15 | 09:30 11:30/13:00 15:00 9:32 ...